Val-Cit-amide-Cbz-N(Me)-Maytansine is a bispecific antibody-drug conjugate (ADC) payload designed to target the c-Met receptor. This research-grade compound is utilized in the development of ADCs for investigating targeted cancer therapies in both in vitro and in vivo models.